Palantir to report; Trump on Nvidia chip exports - what’s moving markets
CARLSBAD, California - Palisade Bio, Inc. (NASDAQ:PALI), a $193 million market cap biotech company, announced Monday that the Canadian Intellectual Property Office has granted patent number 3,174,137 for its lead drug candidate PALI-2108, providing composition-of-matter protection through May 28, 2041. The company’s stock has shown remarkable momentum, surging nearly 187% over the past six months according to InvestingPro data.
The patent, titled "Gut Microbiota Bioactivated PDE4 Inhibitor Precursors," covers the company’s orally administered PDE4 B/D inhibitor being developed for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis.
PALI-2108 features a design that incorporates a galactose-derived sugar component allowing for targeted delivery to the terminal ileum and colon. The drug is activated by bacterial enzymes in the lower intestine, which the company says enables high local tissue concentrations while minimizing systemic exposure.
"We remain committed to strengthening the intellectual property portfolio around PALI-2108 and are focused on advancing the development of this program," said J.D. Finley, Chief Executive Officer of Palisade. While the company faces current profitability challenges with negative EBITDA of $12.12 million, InvestingPro data shows analysts maintain a bullish outlook with price targets ranging from $2 to $14.
The clinical-stage biopharmaceutical company is currently advancing PALI-2108 in a Phase 1b study for FSCD, with patient dosing expected to begin in the second half of 2025 and topline data anticipated in the first quarter of 2026.
Palisade Bio plans to submit a Phase 2 Investigational New Drug (IND) application to the U.S. Food and Drug Administration in the first half of 2026, based on data from both the FSCD Phase 1b trial and previously completed Phase 1a/1b trials in ulcerative colitis.
According to the company’s press release statement, PALI-2108 is designed to address tolerability issues such as nausea and headache that have historically limited systemic PDE4 inhibitors. With the next earnings report due on November 11, 2025, investors tracking this development can access comprehensive financial analysis and 12 additional exclusive insights through InvestingPro.
In other recent news, Palisade Bio, Inc. announced the successful closing of a public offering, raising approximately $138 million in gross proceeds. This offering included the full exercise of the underwriter’s over-allotment option and involved 197,154,844 shares of common stock priced at $0.70 per share. Earlier, the company had priced an underwritten public offering of 171,440,559 shares at the same price, expecting to raise about $120 million. Additionally, Palisade Bio adjourned its special stockholder meeting due to a lack of quorum, with fewer than one-third of outstanding shares represented. The meeting is set to reconvene on October 10, 2025, with no changes to the proposals to be voted on. The record date for determining stockholders entitled to vote remains July 28, 2025. These developments reflect Palisade Bio’s ongoing efforts to secure funding and engage with its shareholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.